HDAX Therapeutics is a startup based in the United States, 3 tracked investors.
HDAX Therapeutics is a company headquartered in the United States. Brouky records 3 investors associated with the company.
HDAX Therapeutics develops potent, selective small molecule inhibitors targeting HDAC6 for treating neurological and cardiovascular diseases, leveraging a proprietary 2-site binding mechanism.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.